clavulanic acid has been researched along with ppi-0903 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ge, Y; Kaniga, K; Livermore, DM; Mushtaq, S; Warner, M | 1 |
Arthur, M; Ourghanlian, C; Soroka, D | 1 |
2 other study(ies) available for clavulanic acid and ppi-0903
Article | Year |
---|---|
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Topics: Acinetobacter; Anti-Bacterial Agents; Bacteria; Bacterial Proteins; Bacteroides; beta-Lactamases; Ceftaroline; Cephalosporins; Clavulanic Acid; Conjugation, Genetic; Drug Combinations; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Enterococcus; Escherichia coli; Gram-Negative Bacteria; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Phenotype; Respiratory Tract Diseases; Staphylococcus | 2007 |
Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
Topics: Amino Acid Motifs; Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftaroline; Ceftazidime; Cephalosporins; Clavulanic Acid; Cloning, Molecular; Drug Combinations; Escherichia coli; Gene Expression; Kinetics; Mutation; Recombinant Proteins; Reverse Genetics; Substrate Specificity | 2017 |